2. Signaling Pathways
  3. Anti-infection
  4. EBV

EBV

Epstein-Barr Virus

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives. EBV spreads most commonly through bodily fluids, primarily saliva. Primary EBV infection is usually asymptomatic and for many occurs during childhood, but when it occurs in adolescence or adulthood, 30%–50% cases manifest clinically as infectious mononucleosis (IM). EBV also cause infectious mononucleosis (IM), Burkitt lymphoma (BL), nasopharyngeal carcinoma (NPC), Hodgkin’s disease, and other illnesses. Many people become infected with EBV in childhood. EBV infections in children usually do not cause symptoms, or the symptoms are not distinguishable from other mild, brief childhood illnesses.

EBV Related Products (75):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12336
    NIBR189
    		99.71%
    NIBR189 is an EBI2 (Epstein-Barr virus-induced gene 2) antagonist. NIBR189 inhibits human and mouse EBI2 with IC50s of 11 and 16 nM, respectively. NIBR189 can be used for the research of autoimmune diseases.
    NIBR189
  • HY-16305
    Maribavir
    		99.96%
    Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC50 of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).
    Maribavir
  • HY-W725179
    VK-2019
    		Inhibitor 99.97%
    VK-2019 is an orally bioavailable selective inhibitor of EBNA1. By binding to the protein-DNA interface to interfere with the recruitment and anchoring of the viral DNA replication machinery, VK-2019 effectively blocks the replication and proliferation of EBV in latently infected cells. VK-2019 reduces the copy number and gene expression level of Epstein-Barr virus in tumor cells, decreases the number of EBER-positive cells, and exhibits significant antiviral, immunomodulatory and antiproliferative activities. VK-2019 successfully inhibits tumor growth in EBV-dependent xenograft models. VK-2019 has favorable systemic exposure and acceptable safety profiles, and is widely used in research on advanced nasopharyngeal carcinoma and various EBV-associated cancers.
    VK-2019
  • HY-N7015
    Zerumbone
    		99.74%
    Zerumbone is an orally active natural cyclic sesquiterpene and can be isolated from Zingiber zerumbet. Zerumbone has anti-proliferative, anti-inflammation, anti-cancer, anti-bacterial and anti-mutagenic activity.
    Zerumbone
  • HY-B0277
    Vidarabine
    		Inhibitor 99.35%
    Vidarabine (Ara-A) is a nucleoside antibiotic isolated from Streptomyces, and a metabolite of Vidarabine phosphate (HY-B0277A). Vidarabine selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.
    Vidarabine
  • HY-N19721
    Brasimarin B
    Brasimarin B is a 4-phenylcoumarin compound found in the stem bark of Calophyllum brasiliense. Brasimarin B inhibits TPA (HY-18739)-induced EBV-EA activation in Raji cells.
    Brasimarin B
  • HY-N13723
    Methyl lucidenate D
    		Inhibitor
    Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation with an IC50 of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention.
    Methyl lucidenate D
  • HY-183552
    mCPX
    mCPX is a prodrug of the antifungal agent Ciclopirox olamine (CPX) (HY-B0450A). CPX exhibits bacteriostatic and iron-chelating activities, while mCPX enhances the iron stability of CPX. mCPX inherits the core mechanism pathway of CPX and can induce EBV lytic reactivation in EBV+ gastric cancer cells via the hypoxia pathway (HIF‑1α). mCPX is applicable to research related to EBV-positive gastric cancer.
    mCPX
  • HY-N0649
    Narcissin
    		Inhibitor 99.82%
    Narcissin (Narcissoside), a flavonol glycoside, exhibits evident scavenging activity against both authentic ONOO- and SIN-1-derived ONOO- with IC50s of 3.5 and 9.6 μM, respectively.
    Narcissin
  • HY-125471
    VK-1727
    		Inhibitor 99.88%
    VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research.
    VK-1727
  • HY-B0277A
    Vidarabine phosphate
    		Inhibitor 99.44%
    Vidarabine phosphate (ara-AMP; ara-A 5'-monophosphate) is a purine nucleoside antiviral agent and a prodrug of Vidarabine (HY-B0277). Vidarabine phosphate is rapidly converted into the antiviral active Vidarabine in vivo, which selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.
    Vidarabine phosphate
  • HY-N6033
    Ferruginol
    Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities.
    Ferruginol
  • HY-133108
    Azadirachtin B
    		99.17%
    Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the Epstein-Barr virus early antigen (EBV-EA). Azadirachtin B has insecticidal, nematocidal, anticancer, anti-inflammatory, antiviral and osteogenic properties.
    Azadirachtin B
  • HY-119098
    GSK983
    		Inhibitor 99.8%
    GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.
    GSK983
  • HY-B2117
    Valpromide
    		Inhibitor 99.72%
    Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.
    Valpromide
  • HY-N2006
    Ganoderic acid B
    		99.60%
    Ganoderic acid B is a triterpene isolated from a mushroom Ganoderma lucidum. Ganoderic acid B inhibits the activation of Epstein-Barr virus (EBV) antigens as telomerase inhibitor. Ganoderic acid B is a moderately active inhibitor against HIV-1 protease (IC50: 170 μM).
    Ganoderic acid B
  • HY-131236
    EBNA1-IN-SC7
    		98.37%
    EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC50 value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research.
    EBNA1-IN-SC7
  • HY-149577
    EBV lytic cycle inducer-1
    		Inducer
    Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers.
    EBV lytic cycle inducer-1
  • HY-N7691
    3,29-O-Dibenzoyloxykarounidiol
    		99.79%
    3,29-O-Dibenzoyloxykarounidiol (Karounidiol dibenzoate) is a triterpene benzoate isolated from the fruit of Momordica grosvenori. 3,29-O-Dibenzoyloxykarounidiol has potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) induced by tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA).
    3,29-O-Dibenzoyloxykarounidiol
  • HY-P5470
    LMP2A (426-434)
    LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8+ IFN-γ+ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .
    LMP2A (426-434)